LTGO-33 is a potent and selective inhibitor of voltage-gated sodium channel NaV1.8. LTGO-33, with its potency in the nanomolar range, selectively inhibits NaV1.8 over 600 times more than human NaV1.1-NaV1.7 and NaV1.9. Its inhibition is not dependent on the state of the channels and displays consistent potency against both closed and inactivated conformations. LTGO-33 holds […]

LTGO-33 is a potent and selective inhibitor of voltage-gated sodium channel NaV1.8. LTGO-33, with its potency in the nanomolar range, selectively inhibits NaV1.8 over 600 times more than human NaV1.1-NaV1.7 and NaV1.9. Its inhibition is not dependent on the state of the channels and displays consistent potency against both closed and inactivated conformations. LTGO-33 holds […]

PF-05251749 (CK1-IN-2, Compound Nr.4) is a potent, selective, brain-penetrant inhibitor of Casein Kinase 1 (CK1) in a concentration-dependent manner, with IC50 values of 33.1 nM for CK1d and 51.6 nM for CK1e. It also functions as an inducer of CYP3A, with the potential to treat circadian rhythm disruptions in Alzheimer’s and Parkinson’s diseases.

PF-05251749 (CK1-IN-2, Compound Nr.4) is a potent, selective, brain-penetrant inhibitor of Casein Kinase 1 (CK1) in a concentration-dependent manner, with IC50 values of 33.1 nM for CK1d and 51.6 nM for CK1e. It also functions as an inducer of CYP3A, with the potential to treat circadian rhythm disruptions in Alzheimer’s and Parkinson’s diseases.

PF-05251749 (CK1-IN-2, Compound Nr.4) is a potent, selective, brain-penetrant inhibitor of Casein Kinase 1 (CK1) in a concentration-dependent manner, with IC50 values of 33.1 nM for CK1d and 51.6 nM for CK1e. It also functions as an inducer of CYP3A, with the potential to treat circadian rhythm disruptions in Alzheimer’s and Parkinson’s diseases.

PF-05251749 (CK1-IN-2, Compound Nr.4) is a potent, selective, brain-penetrant inhibitor of Casein Kinase 1 (CK1) in a concentration-dependent manner, with IC50 values of 33.1 nM for CK1d and 51.6 nM for CK1e. It also functions as an inducer of CYP3A, with the potential to treat circadian rhythm disruptions in Alzheimer’s and Parkinson’s diseases.

IBG1 (PROTAC BRD4 Degrader-19) is a PROTAC-like degrader specifically targeting BET bromodomains with a DC50 of 0.15 nM for BRD4. It consists of the BET inhibitor JQ1 linked to E7820 and functions through CRL4-DCAF16.

IBG1 (PROTAC BRD4 Degrader-19) is a PROTAC-like degrader specifically targeting BET bromodomains with a DC50 of 0.15 nM for BRD4. It consists of the BET inhibitor JQ1 linked to E7820 and functions through CRL4-DCAF16.

IBG1 (PROTAC BRD4 Degrader-19) is a PROTAC-like degrader specifically targeting BET bromodomains with a DC50 of 0.15 nM for BRD4. It consists of the BET inhibitor JQ1 linked to E7820 and functions through CRL4-DCAF16.

IBG1 (PROTAC BRD4 Degrader-19) is a PROTAC-like degrader specifically targeting BET bromodomains with a DC50 of 0.15 nM for BRD4. It consists of the BET inhibitor JQ1 linked to E7820 and functions through CRL4-DCAF16.